PLOVER BAY TECH (01523): Fu Jinxiang, Liu Jianpei and Yu Minhua appointed as independent non-executive directors.
Hengwan Technology (01523) announced that, effective from June 1, 2026, Mr. Fu Jinxiang has been appointed as an independent non-executive director, and also appointed as the chairman of the Nomination Committee, as well as a member of the Audit Committee and Remuneration Committee; Mr. Liu Jianpei has been appointed as an independent non-executive director, and also appointed as the chairman of the Remuneration Committee, as well as a member of the Audit Committee; Ms. Yu Minhua has been appointed as an independent non-executive director, and also appointed as the chairman of the Audit Committee, as well as a member of the Nomination Committee.
PLOVER BAY TECH (01523) announced that with effect from 1 June 2026, Mr. Fu Jinxiang has been appointed as an independent non-executive director and appointed as the chairman of the Nomination Committee, as well as a member of the Audit Committee and Remuneration Committee; Mr. Liu Jianpei has been appointed as an independent non-executive director and appointed as the chairman of the Remuneration Committee, as well as a member of the Audit Committee; Ms. Yu Minhua has been appointed as an independent non-executive director and appointed as the chairman of the Audit Committee, as well as a member of the Nomination Committee.
Related Articles
XIAO NOODLES (02408) spent HK$1.4016 million to repurchase 33,650 shares on June 1st.
Innovative Medical Management (002173.SZ) plans to repurchase company shares worth 50 million to 100 million yuan.
Sichuan Biokin Pharmaceutical (688506.SH) plans to repurchase shares worth 100 million to 200 million yuan.
XIAO NOODLES (02408) spent HK$1.4016 million to repurchase 33,650 shares on June 1st.
Innovative Medical Management (002173.SZ) plans to repurchase company shares worth 50 million to 100 million yuan.
Sichuan Biokin Pharmaceutical (688506.SH) plans to repurchase shares worth 100 million to 200 million yuan.
